Senate Bill No. 933, titled the Right to Try for Individualized Treatments Act, establishes a framework for eligible patients to access individualized investigational treatments for life-threatening or severely debilitating illnesses. The bill defines key terms such as "eligible facility," "eligible patient," and "individualized investigational treatment," and outlines the conditions under which patients can seek these treatments. It emphasizes that participation in this act is voluntary for manufacturers and payors, and it does not mandate coverage or services from insurers or healthcare facilities. Additionally, the bill provides certain immunities from civil liability for manufacturers and healthcare providers involved in the treatment process.

The legislation also includes provisions to protect healthcare providers from disciplinary actions based solely on their recommendations for individualized investigational treatments. It ensures that patients' heirs are not liable for debts related to treatments if the patient dies while receiving such care. Furthermore, the act prohibits state entities from obstructing access to these treatments, while allowing healthcare providers to offer counseling and recommendations in line with medical standards. The bill is set to take effect on November 1, 2026.